Unknown

Dataset Information

0

Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome.


ABSTRACT: Glasdegib is a Hedgehog pathway inhibitor. This phase II, randomized, open-label, multicenter study (ClinicalTrials.gov, NCT01546038) evaluated the efficacy of glasdegib plus low-dose cytarabine (LDAC) in patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome unsuitable for intensive chemotherapy. Glasdegib 100?mg (oral, QD) was administered continuously in 28-day cycles; LDAC 20?mg (subcutaneous, BID) was administered for 10 per 28 days. Patients (stratified by cytogenetic risk) were randomized (2:1) to receive glasdegib/LDAC or LDAC. The primary endpoint was overall survival. Eighty-eight and 44 patients were randomized to glasdegib/LDAC and LDAC, respectively. Median (80% confidence interval [CI]) overall survival was 8.8 (6.9-9.9) months with glasdegib/LDAC and 4.9 (3.5-6.0) months with LDAC (hazard ratio, 0.51; 80% CI, 0.39-0.67, P?=?0.0004). Fifteen (17.0%) and 1 (2.3%) patients in the glasdegib/LDAC and LDAC arms, respectively, achieved complete remission (P?

SUBMITTER: Cortes JE 

PROVIDER: S-EPMC6365492 | biostudies-literature | 2019 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications


Glasdegib is a Hedgehog pathway inhibitor. This phase II, randomized, open-label, multicenter study (ClinicalTrials.gov, NCT01546038) evaluated the efficacy of glasdegib plus low-dose cytarabine (LDAC) in patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome unsuitable for intensive chemotherapy. Glasdegib 100 mg (oral, QD) was administered continuously in 28-day cycles; LDAC 20 mg (subcutaneous, BID) was administered for 10 per 28 days. Patients (stratified by cytogen  ...[more]

Similar Datasets

| S-EPMC8008421 | biostudies-literature
| S-EPMC2878788 | biostudies-literature
| S-EPMC9605800 | biostudies-literature
| S-EPMC7540307 | biostudies-literature
| S-EPMC4879705 | biostudies-literature
| S-EPMC7515941 | biostudies-literature
| S-EPMC4110914 | biostudies-literature
| S-EPMC6127025 | biostudies-literature
| S-EPMC7362563 | biostudies-literature